Left Ventricular Assist Devices (LVAD): Bridge to Transpl...

Cardiac Surgery · 3 · October 28, 2025

The HeartMate 3 (Abbott) — a magnetically levitated centrifugal pump the size of a kiwi fruit — now keeps over 25,000 Americans alive with end-stage heart failure. Originally designed as a temporary bridge while patients waited for transplant, LVADs are increasingly implanted as permanent 'destination therapy' for patients who aren't transplant candidates. Two-year survival with the HeartMate 3: 79%. Without any intervention, end-stage heart failure has a 2-year survival of 8%.

How an LVAD Works

The pump is implanted in the pericardial space and connected to the left ventricle via an inflow cannula. It draws blood from the left ventricle and propels it into the ascending aorta through an outflow graft. A driveline exits the skin (typically in the right upper abdomen) and connects to an external controller and batteries. Patients carry two battery packs, each lasting 10–14 hours. The pump runs continuously — LVAD patients don't have a palpable pulse.

Bridge to Transplant vs. Destination Therapy

Bridge to transplant (BTT): LVAD supports the patient until a donor heart becomes available. 60% of LVAD patients listed for transplant receive a heart within 12 months. The LVAD improves end-organ function, making the patient a better transplant candidate.

Destination therapy (DT): For patients over 72, with irreversible contraindications to transplant, or who simply prefer LVAD. Five-year survival with HeartMate 3: approximately 50% — not as good as transplant (75%) but dramatically better than medical therapy alone (8%).

Costs Worldwide

The HeartMate 3 device costs approximately $100,000. Total implantation cost in the US: $250,000–$400,000. At Fortis Escorts Heart Institute Delhi and Medanta Gurugram, total cost (device + surgery + 3-week hospitalization) runs $50,000–$80,000. The same device — manufactured by Abbott in the same facility — is used worldwide.

Cost Comparison

| Country | Cost Range (LVAD Implantation)

| United States | $250,000–$400,000

| India | $50,000–$80,000

| Turkey | $80,000–$120,000

| Mexico | $100,000–$150,000

Key Takeaways

- LVAD two-year survival: 79% vs. 8% with medical therapy alone for end-stage heart failure.

- Destination therapy (permanent LVAD) offers 50% five-year survival — a viable option when transplant isn't available.

- The HeartMate 3 device costs $100,000 globally — the 5x price gap between US and India is in hospital and surgeon fees.

Compare real-time pricing using our global cost calculator.